Stay tuned for official IASLC press conference information, including scheduled Press Conferences taking place during WCLC 2011. Press materials and teleconferences will be available to U.S. and international media.
For more information, please contact:
Kristal Griffith
IASLC Director of Communications
Email: kristal.griffith@ucdenver.edu
Please also refer to the press page on the IASLC website, click here >>
WCLC 2011 Fact Sheet
Click here for quick information about the 14th World Conference on Lung Cancer >>
Press & Media Registration
Media and Embargo Policy
Click here to download the IASLC WCLC 2011 Media & Embargo Policies (updated 19 April 2011) >>
Press Releases
Online Registration opens for the 14th World Conference on Lung Cancer in Amsterdam
Press Programme announced for the 14th World Conference on Lung Cancer in Amsterdam
IASLC Advocacy Award Winners announced
IASLC Statement on Spiral CT Screening for Lung Cancer
PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
Lung tumors in never-smokers show greater genomic instability than those in smokers
ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy
Increased investment in thoracic surgical expertise increased UK lung cancer resection rate
Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009
Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDA
Canada's Cancer Risk Management model is an important new health tool for policymakers
Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
TEMLA shows higher diagnostic yield than EBUS or EUS in largest reported series to date
Endosonography followed by surgical staging improves quality of life, according to ASTER study
Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux
WCLC 2011 On-site Newsletters
Oncology TV
Oncology TV presents an international news program from the World Conference on Lung Cancer held in Amsterdam from 3-7 July 2011. With her guests professor Giorgio Scagliotti, Dr Roy Herbst, Professor Suresh Senan and Dr Eric Vallieres, presentor Inge Diepman and co-host Professor Egbert Smit discuss several highlights of this conference. Also interviews with Dr John Minna and Dr Andrew Turrisi are included.
Subjects are amongst others:
- maintenance therapy with pemetrexed;
- the FLEX study: new data on the prediction of survival benefit;
- the impact of reorganising thoracic surgery;
- and improved survival with the use of stereotactic radiotherapy;
Please click here to watch the video: www.oncologytv.eu
Press Conferences
Monday, 4 July - 10:00 - 11:00: CT Screening
Tuesday, 5 July - 10:00 - 11:00: Biomarkers and Personalized Therapy
- O01.06 - Epidermal growth factor receptor (EGFR) expression as a predictor of survival for first-line chemotherapy plus cetuximab in FLEX study patients with advanced non-small cell lung cancer (NSCLC) - Robert Pirker, Austria
- O05.01 - ALK fusion and MET amplification as molecular biomarkers and therapeutic targets in advanced lung adenocarcinomas in the Lung Cancer Mutation Consortium - Marileila Varella Garcia, USA
- O07.02 - Lung adenocarcinoma genomes of never smokers exhibit a greater extent of genomic instability than those of smokers - Kelsie Thu, Canada
- O10.01 - The EURTAC (European Tarceva® vs Chemotherapy) study: interim results of a phase III randomized trial of erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mutations - Radj Gervais, France
- PRS.5 - In vivo selection of non-small cell lung cancer patients with activating mutations in the tumor epidermal growth factor receptor using [11C]erlotinib and positron emission tomography - Idris Bahce, The Netherlands
Wednesday, 6 July - 10:00 - 11:00: Improvements in Care (Population-Based Approaches to Treatment)
- O01.05 - PARAMOUNT: Phase III trial results of maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC) - Luiz Paz-Ares, Spain
- O44.02 - A Canadian Cancer Risk Management Model: A New Health Policy Tool Useful in Policy Decisions Related to Lung Cancer. - William Evans, Canada
- O44.06 - Poor representation of Women, Older age group and Minorities in US registration trials for Non-Small Cell Lung Cancer: FDA Review - Shakun Malik, USA
- PRS.3 - Improvements in survival of elderly patients with stage I NSCLC in the Netherlands between 2003-2009 - Cornelis Haasbeek
- PRS.7 - The effects of investing in thoracic surgery on lung cancer resection rates - Kelvin Kar Wing, UK
Thursday, 7 July - 10:00 - 11:00: Improvements in Practice (Practice-Changing Advances)
- O01.02 - Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC) - Joachim von Pawel, Germany
- O03.01 - Comparison of diagnostic yield of endoscopic ultrasound staging of Non-Small Cell Lung Cancer (NSCLC) performed with use of Endobronchial Ultrasound (EBUS) and/or Endoesophageal Ultrasound (EUS) with invasive staging of NSCLC performed with use of Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) - Marcin Zielinski, Poland
- O34.03 - Cost-effectiveness and quality of life results from the ASTER study: Endobronchial and endoscopic ultrasound versus surgical staging in potentially resectable lung cancer - Robert Campbell Rintoul, UK
- O41.07 - Testing the role of adding an inferior vena cava filter (IVCF) to anticoagulation with fondaparinux in patients with cancer and venous thromboemboli (VTE): results of the CAT (Cancer and Thrombosis) prospective randomized clinical trial (RCT) - Richard Gralla, USA
IASLC - International Association for the Study of Lung Cancer
Founded in 1972, the International Association for the Study of Lung Cancer (IASLC) is an international organization of nearly 3,000 lung cancer specialists, spanning 80 countries. IASLC members work towards developing and promoting the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer. IASLC’s mission is to enhance the understanding and education of lung cancer to scientists, members of the medical community and the public. In addition to the biannual meeting, the IASLC publishes the Journal of Thoracic Oncology, a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.